Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,943,790 papers from all fields of science
Search
Sign In
Create Free Account
BIIB022
Known as:
Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022
, BIIB-022
A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Monoclonal Antibodies
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
M. von Mehren
,
C. Britten
,
+8 authors
S. Leong
Investigational new drugs
2014
Corpus ID: 18323668
SummaryPurpose The IGF-1R signaling pathway has been implicated in multiple cancers as important for cell survival, proliferation…
Expand
Review
2012
Review
2012
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
G. Scagliotti
,
S. Novello
Cancer Treatment Reviews
2012
Corpus ID: 35140296
Review
2011
Review
2011
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review
E. Ozkan
Molecular and Cellular Endocrinology
2011
Corpus ID: 37296132
2010
2010
Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.
M. Mehren
,
C. Britten
,
+7 authors
S. Leong
2010
Corpus ID: 74448604
2612 Background: The IGF pathway is believed to play a key role in the pathogenesis of several tumors. BIIB022 is a human…
Expand
Review
2009
Review
2009
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
M. Hewish
,
I. Chau
,
D. Cunningham
Recent Patents on Anti-Cancer Drug Discovery
2009
Corpus ID: 24679137
The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has provoked considerable interest over…
Expand
2009
2009
Dyax and Biogen Idec Expand Drug Discovery Deal
Taskin Ahmed
2009
Corpus ID: 72127064
Biogen Idec has expanded its agreement to discover additional antibody products using Dyax’s phage display drug discovery…
Expand
2009
2009
1227 A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumours
M. Mehren
,
C. Britten
,
+7 authors
S. Leong
2009
Corpus ID: 71394161
2008
2008
BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and Rapamycin in…
Jianying Dong
,
S. Tamraz
,
+7 authors
K. Hariharan
2008
Corpus ID: 74114620
4002 Antibodies to IGF-1R as inhibitors of PI3K/AKT survival pathway have shown evidence of objective responses in early clinical…
Expand
2007
2007
BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy
K. Hariharan
,
Jianying Dong
,
+7 authors
M. Reff
2007
Corpus ID: 89622137
B210 Antibodies targeting human type I insulin-like growth factor receptor (IGF-1R) as inhibitors of tumor survival pathway have…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE